18 completed, 5 recruiting, 3 not yet recruiting, 3 terminated. 34 Phase 1, 18 Phase 2.
Follow salicylhydroxamic acid: new trials by email Literature Review of salicylhydroxamic acid trials Research Report on salicylhydroxamic acid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery BPC-157, Sham (No Treatment) - Rotator Cuff Tear | Phase 1 | Not yet recruiting | University of Arkansas | 30 | 2027-01-01 | 2026-09-03 |
| Noninvasive Neuromodulation Of The Subjective Value Network In Chronic Pain Transcranial magnetic stimulation, Sham - Chronic Neurogenic Pain | Phase 1 | Not yet recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 9 | 2026-12-01 | 2026-09-28 |
| Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection) ZM-02 (low dose), ZM-02 (high dose), ZM-02 (selected dose) - Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Not yet recruiting | Zhongmou Therapeutics | 21 | 2026-06-25 | 2026-04-13 |
| A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy TO-O-1007 (low-dose), TO-O-1007 (high-dose), Sham injection - Geographic Atrophy Due to Age-Related Macular Degeneration | Phase 1 / Phase 2 | Recruiting | Theratocular Biotek Co. | 31 | 2026-06-02 | 2026-06-25 |
| A Study of VV-14305 for the Treatment of Thyroid Eye Disease VV-14305, Sham (No Treatment) - Thyroid Eye Disease (TED) | Phase 1 / Phase 2 | Recruiting | Kriya Therapeutics, Inc. | 135 | 2026-05-01 | 2026-08-27 |
| Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) ST-503, Sham (No Treatment) - Chronic Neuropathic Pain | Phase 1 / Phase 2 | Recruiting | Sangamo Therapeutics | 27 | 2025-12-04 | 2026-06-01 |
| Title Fractioned CO2 Laser in the Treatment of Chronic Phase Peyronie's Disease Fractional CO2 laser, Sham (No Treatment) - Peyronies Disease | Phase 1 | Recruiting | Ottawa Hospital Research Institute | 60 | 2025-10-01 | 2025-09-17 |
| The Herbal Acupoint Patch for Dialysis Patient With Fistula-related Pain Artemisias-ginger patch (AGP), Sham (No Treatment) - End Stage Chronic Renal Failure, Myofacial Pain | Phase 1 / Phase 2 | Completed | Chang Gung Memorial Hospital | 21 | 2024-02-15 | 2026-02-02 |
| GDNF Gene Therapy for Multiple System Atrophy AAV2-GDNF gene therapy, Sham (Placebo) Surgery - Multiple System Atrophy | Phase 1 | Active not recruiting | Brain Neurotherapy Bio, Inc. | 9 | 2023-10-03 | 2026-01-30 |
| Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy OTX-TKI, Sham - Non-proliferative Diabetic Retinopathy | Phase 1 | Unknown | Ocular Therapeutix, Inc. | 21 | 2023-01-15 | 2023-12-08 |
| Safety and Tolerability of EO2002 EO2002, Sham injection - Cataract, Endothelial Cell Loss, Corneal | Phase 1 | Recruiting | Asociación para Evitar la Ceguera en México | 32 | 2022-08-30 | 2025-12-08 |
| Combination of Duloxetine and Pregabalin to Improve Postoperative Pain Duloxetine and Pregabalin, pregabalin, sham - Postoperative Pain | Phase 1 | Completed | Cairo University | 90 | 2021-07-30 | 2026-01-21 |
| ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration ONL1204 Ophthalmic solution, sham injection - Geographic Atrophy | Phase 1 | Completed | ONL Therapeutics | 28 | 2021-07-08 | 2024-11-19 |
| Cold Heart Study: A Randomized Pilot Trial of Surfactant Therapy Curosurf, Sham - Congenital Heart Disease, Hypoplastic Left Heart Syndrome | Phase 1 | Terminated | University of Michigan | 2 | 2020-02-25 | 2023-09-13 |
| Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease intra-striatal rAAV5-miHTT, Imitation (sham) surgery - Huntington's Disease | Phase 1 / Phase 2 | Active not recruiting | UniQure Biopharma B.V. | 43 | 2019-09-06 | 2025-10-21 |
| Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Disc Degeneration IDCT, Sham - Degenerative Disc Disease | Phase 1 | Completed | DiscGenics, Inc. | 38 | 2019-05-23 | 2025-11-20 |
| The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers Exenatide, Sham injection - Alcohol Use Disorder | Phase 1 | Terminated | Boston Medical Center | 8 | 2019-05-02 | 2022-02-09 |
| Effects of Caffeine and Intermittent Hypoxia on Leg Function in Human Spinal Cord Injury Caffeine, AIH, Placebo - Spinal Cord Injuries | Phase 1 / Phase 2 | Completed | Spaulding Rehabilitation Hospital | 36 | 2019-01-01 | 2023-12-13 |
| VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1) VY-AADC02, Sham (Placebo) Surgery - Parkinson's Disease | Phase 1 | Completed | Neurocrine Biosciences | 14 | 2018-10-17 | 2024-12-10 |
| A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema Aflibercept, OPT-302, Sham intravitreal injection - Diabetic Macular Edema | Phase 1 / Phase 2 | Completed | Opthea Limited | 153 | 2018-01-16 | 2025-04-22 |
Showing 20 of 34. Sign in to see all of them.
Geographic Atrophy (2) · Retinitis Pigmentosa (2) · Alcohol Drinking (1) · Alcoholism (1) · Cataract (1) · Chronic Pain (1) · Corneal Endothelial Cell Loss (1) · Deglutition Disorders (1) · Diabetes Mellitus (1) · Diabetic Retinopathy (1) · Facial Pain (1) · Graves Ophthalmopathy (1) · Heart Defects, Congenital (1) · Huntington Disease (1) · Hypoplastic Left Heart Syndrome (1)
Alcon Research (2) · Allergan (1) · Asociación para Evitar la Ceguera en México (1) · Beth Israel Deaconess Medical Center (1) · Boston Medical Center (1) · Brain Neurotherapy Bio, Inc. (1) · Cairo University (1) · Chang Gung Memorial Hospital (1) · Chelsea Therapeutics (1) · DiscGenics, Inc. (1) · Federal University of São Paulo (1) · Imperial College London (1) · Isfahan University of Medical Sciences (1) · Kriya Therapeutics, Inc. (1) · Mohamed R El Tahan (1)
United States (20) · Australia (3) · Egypt (2) · New Zealand (2) · Brazil (1) · Canada (1) · China (1) · France (1) · Germany (1) · Iran (1) · Israel (1) · Japan (1) · Latvia (1) · Mexico (1) · Portugal (1)
Angelino J Cariello, MD (1) · Carl LeBel, PhD (1) · Daniel Meira-Freitas, MD (1) · David H. Margolin, MD, PhD (1) · Dr. Andrew Chang (1) · Eric Devine, PhD (1) · Eric M Wassermann, M.D. (1) · Joan E. Fox, PhD (1) · Jocelyn Y. Ang, MD (1) · Luke Witherspoon (1)
PMID 20351373, PMID 21441148, PMID 25532706, PMID 31072380, PMID 31127735, PMID 31442616, PMID 32250312, PMID 36463457, PMID 38489195, PMID 40235521
2014 (1), R01HD081274 (1), R21AA027332 (1)